Benefits of macrolides in the treatment of asthma

Kadota J, Mukae H, Ishii H et al (2003) Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Resp Med 97: 844–50CrossRefGoogle Scholar

National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, US Department of Health and Human Services, 1997; NIH Publication No. 97-4051Google Scholar

Tamaoki J (2004) The effects of macrolides on inflammatory cells. Chest 125: 41S–51SCrossRefPubMedGoogle Scholar

Gotfried MH (2004) Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125: 52S–61SCrossRefPubMedGoogle Scholar

Khair OA, Devalia JL, Abdelaziz et al (1995) Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8, and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 8: 1451–7PubMedGoogle Scholar

Takizawa H, Desaki M, Ohtoshi M et al (1995) Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 210: 781–6CrossRefPubMedGoogle Scholar

Kawasaki S, Takizawa H, Takayuki O, et al (1998) Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 42: 1499–502PubMedGoogle Scholar

Schultz M, Speelman P, Zaat S, et al (1998) Erythromycin inhibits tumor necrosis factor alpha killed and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 42: 1605–9PubMedGoogle Scholar

Konno S, Asano K Kurokawa M, et al (1994) Antiasthmatic activity of a macrolide antibiotic, roxithromycin: Analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 105: 308–16PubMedGoogle Scholar

Aoki Y, Kao PN (1999) Erythromycin inhibits transcriptional activation of NF-κB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 43: 2678–84PubMedGoogle Scholar

Ichiyama T, Nishikawa M, Yoshitomi T et al (2001) Clarithromycin inhibits NF-ºB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45: 44–7CrossRefPubMedGoogle Scholar

Abe S, Nakamura H, Inoue S et al (2000) Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 22: 51–60PubMedGoogle Scholar

Desaki M, Takizawa H, Ohtoshi T et al (2000) Erythromycin suppresses nuclear factor-κB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Comm 267: 124–8CrossRefPubMedGoogle Scholar

Kikuchi T, Hagiwara K Honda Y, et al (2002) Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 49: 745–55CrossRefPubMedGoogle Scholar

Baggiolini M, Wlz A, Kunkel SL (1989) Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J Clin Invest 84: 1045–9PubMedGoogle Scholar

Standiford TJ, Kunkel SL, Basha MA et al (1990) Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J Clin Invest 86: 1945–53PubMedGoogle Scholar

Shibata Y, Nakamura H, Kato S et al (1996) Cellular detachment and deformation induce IL-8 gene expression in human bronchial epithelial cells. J Immunol 156: 772–7PubMedGoogle Scholar

Fujii T, Kadota JI, Morikawa T et al (1996) Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha, 25-dihydroxyvitamin D3-stimulated THP-1 cells. Antimicrob Agents Chemother 40: 1548–51PubMedGoogle Scholar

Tamaoki J, Takeyama K, Yamawaki I et al (1997) Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 272: L15–L19PubMedGoogle Scholar

Miyajima M, Suga M, Nakagawa K et al (1999) Effect of erythromycin on experimental extrinsic allergic alveolitis. Clin Exp Allergy 29: 253–61CrossRefPubMedGoogle Scholar

Fujii Y, Goldberg P, Hussain SNA (1998) Contribution of macrophages to pulmonary nitric oxide production in septic shock. Am J Respir Crit Care Med 157: 1645–51PubMedGoogle Scholar

Kennedy NJ, Duncan AW (1996). Acute meningococcaemia: recent advances in management (with particular reference to children. Anaesth Intensive Care 24: 197–216PubMedGoogle Scholar

Tamaoki J, Kondo M, Kohri K et al (1999) Macrolide antibiotics protect against immune-complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 163: 2915–29Google Scholar

Labro MT, El Benna J, Babin-Chevaye C (1989) Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 24: 561–72PubMedGoogle Scholar

Hand WL, Hand D, King-Thompson N (1990). Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 34: 863–70PubMedGoogle Scholar

Anderson R (1989) Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant activated superoxide generation and autooxidation. J Infect Dis 5: 966–72Google Scholar

Theron AJ, Feldman C, Anderson R (2000) Investigation of the anti-inflammatory and membrane-stabilizing potential of spiramycin in vitro. J Antimicrob Chemother 46:263–71CrossRefPubMedGoogle Scholar

Takizawa H, Desaki M, Ohitoshi T et al (1998) Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Resp J 12: 57–63CrossRefGoogle Scholar

Scaglione F, Rossoni G (1998) Comparative anti-inflammatory effects of roxithromycin, azithromycin, and clarithromycin. J Antimicrob Chemother 41(Suppl B): 47–50CrossRefGoogle Scholar

Agen C, Danesi R, Blandizzi C et al (1993) Macrolide antibiotics as anti-inflammatory agents: roxithromycin in an unexpected role. Agents Actions 38: 85–90PubMedGoogle Scholar

Kaplan MA, Goldin M (1959) The use of triacetyloleandomycin in chronic infectious asthma. In: Welsh H, Marti-Ibanez F (eds): Antibiotic Annual 1958–1959. Interscience Publishers, New York, NY, 273–6Google Scholar

Zieger RS, Schatz M, Sprerling W et al (1980) Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 66: 438–46CrossRefPubMedGoogle Scholar

Wald JA, Friedman BF, Farr RS (1986)An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma. J Allergy Clin Immunol 78: 36–43PubMedGoogle Scholar

Ball BD, Hill MR, Brenner M et al (1990) Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy 65: 37–45PubMedGoogle Scholar

Flotte TR, Loughlin GM (1991) Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma. Pediatr Pulmonol 10: 178–82PubMedGoogle Scholar

Kamada AK, Hill MR, Ikle DN et al (1993) Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 91: 873–82CrossRefPubMedGoogle Scholar

Eitches RW, Rachelefsky GS, Katz RM et al (1985) Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children. Am J Dis Child 139: 264–8PubMedGoogle Scholar

Siracusa A, Brugnami G, Fiordi T et al (1993) Troleandomycin in the treatment of difficult asthma. J Allergy Clin Immunol 92: 677–82CrossRefPubMedGoogle Scholar

Spector S, Katz F, Farr R (1974) Troleandomycin: effectiveness in steroid dependent asthma and bronchitis. J Allergy Clin Immunol 54: 367–79CrossRefGoogle Scholar

Weinberger M, Hudgel D, Spector S, Chisey C (1977) Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 59: 228 31CrossRefPubMedGoogle Scholar

Rosenberg SM, Gerhard H, Grunstein MM (1991) Use of TAO without methylprednisolone in the treatment of severe asthma. Chest 100: 849 50PubMedGoogle Scholar

Spahn JD, Fost DA, Covar R et al (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87: 501–5PubMedGoogle Scholar

Miyatake H, Taki F, Taniguchi H et al (1991) Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 99: 670–3PubMedGoogle Scholar

Amayasu H, Yoshida S, Ebana S et al (2000) Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 84: 594–8PubMedGoogle Scholar

Shimizu T, Kato M, Mochizuki H et al (1994) Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 106: 458–61PubMedGoogle Scholar

Ekici A, Ekici M, Erdemoglu AK (2002) Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 39(2): 181–5CrossRefPubMedGoogle Scholar

Gotfried MH, Jung R, Messick C et al (2004) Effects of six week clarithromycin therapy in corticosteroid-dependent asthma: A randomized double-blind, placebo-controlled pilot study. Curr Ther Res 65: 1–12CrossRefGoogle Scholar

Garey KW, Rubinstein I, Gotfried MH et al (2000) Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118: 1826–7CrossRefPubMedGoogle Scholar

Shoji T, Yoshida S, Sakamoto H et al (1999) Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 29: 950–6CrossRefPubMedGoogle Scholar

Kamoi H, Kurihara N, Fujiwara H et al (1995) The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma 32: 191–7PubMedGoogle Scholar

Shimizu T, Kato M, Mochizuki H et al (1997) Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma. J Asthma 34:211–17PubMedGoogle Scholar

Emre U, Roblin PM, Gelling M et al (1994) The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 148:727–32PubMedGoogle Scholar

Hahn DL, Bukstein D, Luskin A et al (1998) Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. Ann Allergy Asthma Immunol 80: 45–9PubMedGoogle Scholar

Kraft M, Cassell GH, Henson JE et al (1998) Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 158: 998–1001PubMedGoogle Scholar

Black PN, Scicchitano R, Jenkins CR et al (2000) Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 15: 254–9CrossRefPubMedGoogle Scholar

Waites KB, Cassell GH, Canupp KC et al (1988) In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother 32: 1500–2PubMedGoogle Scholar

Fenelon LE, Mumtaz G, Ridgway GL (1990) The in vitro antibiotic susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 26: 763–7PubMedGoogle Scholar

Critchley IA, Jones ME, Heinze PD et al (2002) In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 8:214–21CrossRefPubMedGoogle Scholar

Hammerschlag MR, Qumei KK, Roblin PM (1992) In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 36: 1573–4PubMedGoogle Scholar

Renaudin H, Bebear C (1990) Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 9:838–41CrossRefPubMedGoogle Scholar

Kraft M, Cassell GH, Pak J et al (2002) Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 121: 1782–8.CrossRefPubMedGoogle Scholar

Cook PJ, Davies P, Tunnicliffe W et al (1998) Chlamydia pnuemoniae and asthma. Thorax 53: 254–9PubMedGoogle Scholar

Hahn DL, Dodge RW, Golubjatnikov R (1991) Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis and adult onset asthma. J Am Med Assoc 266: 255–30CrossRefGoogle Scholar

Wark PA, Johnston SL, Simpson SL et al (2002) Chlamydia pneumoniae immunoglobulin A reaction and airway inflammation in acute asthma. Eur Respir J 20: 834–40CrossRefPubMedGoogle Scholar

Hahn DL, Golubjatnikov R (1994) Asthma and chlamydial infection: a case series. J Fam Pract 38: 589–95PubMedGoogle Scholar

Kraft M, Cassell GH, Bettinger CM et al (2004) Mycoplasma pneumoniae as a cofactor in chronic asthma [abstract]. Available at: www.abstracts-on-line.com/abstracts/ ATSALL. Accessed January 12, 2004Google Scholar

Black PN, Blasi F, Jenkins CR et al (2001) Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 164: 536–41PubMedGoogle Scholar